Capricor Therapeutics, Inc.
CAPR
$6.39
-$0.21-3.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.39M | 17.36M | 22.27M | 23.23M | 27.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.39M | 17.36M | 22.27M | 23.23M | 27.15M |
| Cost of Revenue | 67.33M | 57.78M | 49.97M | 45.35M | 43.58M |
| Gross Profit | -53.93M | -40.42M | -27.70M | -22.13M | -16.42M |
| SG&A Expenses | 19.48M | 16.86M | 14.87M | 14.02M | 13.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.80M | 74.65M | 64.84M | 59.38M | 57.16M |
| Operating Income | -73.41M | -57.28M | -42.56M | -36.15M | -30.00M |
| Income Before Tax | -69.98M | -55.06M | -40.47M | -34.11M | -27.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.98 | -55.06 | -40.47 | -34.11 | -27.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.98M | -55.06M | -40.47M | -34.11M | -27.95M |
| EBIT | -73.41M | -57.28M | -42.56M | -36.15M | -30.00M |
| EBITDA | -71.78M | -55.78M | -41.14M | -34.79M | -28.73M |
| EPS Basic | -1.64 | -1.42 | -1.20 | -1.06 | -0.93 |
| Normalized Basic EPS | -1.02 | -0.88 | -0.75 | -0.66 | -0.58 |
| EPS Diluted | -1.64 | -1.42 | -1.20 | -1.06 | -0.93 |
| Normalized Diluted EPS | -1.02 | -0.88 | -0.75 | -0.66 | -0.58 |
| Average Basic Shares Outstanding | 168.95M | 155.08M | 140.80M | 126.95M | 119.68M |
| Average Diluted Shares Outstanding | 168.95M | 155.08M | 140.80M | 126.95M | 119.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |